Austar Lifesciences Ltd. stock analysis
Want to see HK:6118 full AI Analyst Report?
Austar Lifesciences Ltd. (6118) Stock Price & Analysis
6118 Stock Chart & Stats
- Day’s Range
- HKD 0.46 - HKD 0.52
- 52-Week Range
- HKD 0.46 - HKD 1.08
- Previous Close
- HKD 0.55
- Volume
- N/A
- Average Volume (3M)
- 86.40K
- Market Cap
- HKD 258.85M
- Enterprise Value
- HKD 485.11M
- Total Cash (Recent Filing)
- HKD 255.32M
- Total Debt (Recent Filing)
- HKD 268.24M
- Price to Earnings (P/E)
- 12.8
- Beta
- 0.80
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- May 19, 2015
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Profitability Recovery
The return to positive EBIT, EBITDA, and net income shows that the business has regained profitability after the 2023 loss. If maintained, this recovery can support internal funding, reinforce operating resilience, and provide a more stable base for growth over the next several quarters.
Improved Balance Sheet
Lower leverage and a sizable equity base improve financial flexibility compared with 2023. This gives Austar greater capacity to absorb business volatility, fund customer-related projects, and manage obligations without relying as heavily on additional borrowing.
Positive Recent Cash Generation
Strong recent operating and free cash flow indicates that reported recovery has been accompanied by cash generation rather than relying solely on accounting earnings. This supports working-capital needs, ongoing investment, and financial flexibility across the life-sciences services business.
Bears Say
Thin Margins And Returns
Low net margin and modest ROE show that profitability remains thin relative to the company’s revenue base and capital employed. This leaves less room to absorb execution pressure or cost increases and means the earnings rebound has not yet translated into strong returns.
Uneven Revenue Growth
The uneven revenue trajectory points to limited consistency in demand or project conversion across recent years. Even with a return to growth, only modest expansion reduces operating leverage and makes it harder for Austar to build durable earnings momentum over the medium term.
Volatile Cash-Flow Track Record
Recent cash generation is encouraging, but the history of negative operating and free cash flow indicates meaningful variability in cash conversion. The 2025 decline in free cash flow reinforces that earnings recovery may not consistently translate into increasing cash available for investment or obligations.
Austar Lifesciences Ltd. News
Austar Lifesciences Sets 2026 AGM to Approve Results, Board Mandates and Share Issue Authority
Austar Lifesciences Ltd. ( ($HK:6118) ) has provided an announcement. Austar Lifesciences Limited has called its annual general meeting for 22 May 2026 in Shanghai, where shareholders will review and
Austar Lifesciences Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Austar Lifesciences Ltd. ( ($HK:6118) ) just unveiled an announcement. Austar Lifesciences Limited has scheduled a board meeting for 26 March 2026 to review and approve the group’s annual results
6118 FAQ
What was Austar Lifesciences Ltd.’s price range in the past 12 months?
What is Austar Lifesciences Ltd.’s market cap?
When is Austar Lifesciences Ltd.’s upcoming earnings report date?
How were Austar Lifesciences Ltd.’s earnings last quarter?
Is Austar Lifesciences Ltd. overvalued?
Does Austar Lifesciences Ltd. pay dividends?
What is Austar Lifesciences Ltd.’s EPS estimate?
How many shares outstanding does Austar Lifesciences Ltd. have?
What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Austar Lifesciences Ltd. Stock Smart Score
Company Description
Austar Lifesciences Ltd.
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kwok Keung
- Employees
- 1,468
- Website
- www.austar.com.hk
- Address
- CN
Austar Lifesciences Ltd. (6118) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 4 | 0 | 8 |









